CoChat

Minocycline as adjunctive treatment for major depressive disorder: Pooled data from two randomized controlled trials

Open access

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

Background: Randomized controlled clinical trials that have investigated minocycline as an adjunctive treatment for major depressive disorder have proved promising. Data from two studies were pooled to evaluate more definitively whether the addition of minocycline to standard treatment for major depressive disorder leads to an improvement of depressive symptoms when compared with placebo. Methods: Both studies were multi-site, double-blinded, placebo-controlled trials of minocycline 200 mg/day added to treatment as usual during a 12-week period. The primary outcome measure was change in depressive symptoms (Montgomery–Asberg Depression Rating Scale in Dean et al. and Hamilton Depression Rating Scale in Husain et al.). Secondary outcomes were change in depression severity (Montgomery–Asberg Depression Rating Scale for Dean et al. and 9-item Patient Health Questionnaire in Husain et al.), anxiety severity (Hamilton Anxiety Rating Scale in Dean et al. and Generalized Anxiety Disorder 7-item scale in Husain et al.) and functional status, which were also evaluated as potential mediators on the primary outcome. Results: A total of 112 participants were included in the pooled data (Dean et al., n = 71; Husain et al., n = 41). A significant change from baseline to week 12 was noted in depressive symptoms – differential change (Placebo vs Minocycline): 9.0, 95% confidence interval = [4.2, 13.9], Cohen’s D (95% confidence interval): 0.71 [0.29, 1.14], p < 0.001 – anxiety severity – differential change (Placebo vs Minocycline): 0.38, confidence interval = [0.00, 0.75], Cohen’s D (95% confidence interval): 0.41 [0.00, 0.82], p = 0.050) and functional status – differential change (Placebo vs Minocycline): 1.0, 95% confidence interval = [0.4, 1.5], Cohen’s D (95% confidence interval): 0.76 [0.34, 1.19], p = 0.001). Duration of illness, current use of benzodiazepine and pain medication were identified as moderators, whereas functional status as a mediator/predictor. Conclusion: The improvement of depressive symptoms, anxiety severity and functional status is promising and suggests that minocycline has potential as an adjunctive treatment for major depressive disorder. However, further studies are warranted to confirm therapeutic effects of minocycline in major depressive disorder. Trial registrations: NCT02263872, registered October 2014, and ACTRN12612000283875, registered March 2012.

Overview

Integrity signals

Registry

Crossref · 10.1177/0004867420965697

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

The citation lists are queued

They are fetched later and appear here then.

References 50 · Cited by 31

Research works printed but not linked: 2

  1. IBM Corp, 2015, IBM SPSS Statistics
  2. Maes M, 2008, Neuro Endocrinology Letters, 29, 117

Metadata

Authors
Zazula, R., Husain, M. I., Mohebbi, M., Walker, A. J., Chaudhry, I. B., Khoso, A. B., Ashton, M. M., Agustini, B., Husain, N., Deakin, J., Young, A. H., Berk, M., Kanchanatawan, B., Ng, C. H., Maes, M., Berk, L., Singh, A. B., Malhi, G. S., & Dean, O. M.
Affiliations
  • Universidade Estadual de Londrina (BR)
  • Centre for Addiction and Mental Health (CA)
  • Barwon Health (AU)
  • University of Manchester (GB)
  • Pakistan Institute of Learning and Living (PK)
  • King's College London (GB)
  • Chulalongkorn University (TH)
  • The University of Melbourne (AU)
  • The University of Sydney (AU)
Corresponding author
Zazula, Robson
Venue
Australian & New Zealand Journal of Psychiatry
Published
2020-10-22
Volume
55
Issue
8
Pages
784-798
ISSN
  • 0004-8674 (ISSN-L)
  • 1440-1614
OpenAlex
W3093598617
Cited by
31
References
50
Citations by year
2026: 2 · 2025: 7 · 2024: 4 · 2023: 6 · 2022: 8 · 2021: 4
FWCI
2.70
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Australian & New Zealand Journal of Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • Figshare (submittedVersion, cc-by)
Funders
  • Pakistan Institute of Living and Learning
  • brain and behavior research foundation
  • national institute for health research
  • Australasian Society for Bipolar and Depressive Disorders
  • Simons Autism Foundation
  • stanley medical research institute
  • deakin university
  • Lilly
  • national health and medical research council
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords
major depressive disorder, adjunctive therapy, tetracycline antibiotics, depressive symptoms, anxiety levels, functional status, depression severity, moderators, mediators, disease duration, benzodiazepine use, analgesics, pooled analysis, Hamilton Depression Rating Scale, Montgomery-Asberg Depression Rating Scale, Patient Health Questionnaire
MeSH terms
Major Depressive Disorder, Double-Blind Method, Humans, Minocycline, Psychiatric Status Rating Scales, Randomized Controlled Trials as Topic, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Minocycline as adjunctive treatment for major depressive disorder: Pooled data from two randomized controlled trials. https://app.cochat.ai/papers/10.1177/0004867420965697
The paper
Zazula, R., Husain, M. I., Mohebbi, M., Walker, A. J., Chaudhry, I. B., Khoso, A. B., Ashton, M. M., Agustini, B., Husain, N., Deakin, J., Young, A. H., Berk, M., Kanchanatawan, B., Ng, C. H., Maes, M., Berk, L., Singh, A. B., Malhi, G. S., & Dean, O. M. (2021). Minocycline as adjunctive treatment for major depressive disorder: Pooled data from two randomized controlled trials. Australian & New Zealand Journal of Psychiatry. https://doi.org/10.1177/0004867420965697

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.